Champix is a film-coated tablet taken by mouth as part of a planned stop-smoking programme. It contains varenicline and is prescribed for adults who want to stop smoking. Varenicline reduces nicotine…
Champix is a film-coated tablet taken by mouth as part of a planned stop-smoking programme. It contains varenicline and is prescribed for adults who want to stop smoking. Varenicline reduces nicotine cravings and makes cigarettes less rewarding.
Champix is a prescription stop-smoking treatment containing varenicline, a non-nicotine medicine that acts on nicotine receptors in the brain. It belongs to the pharmacological treatments used to support smoking cessation.
Champix contains varenicline, a prescription stop-smoking treatment that acts on nicotine receptors in the brain. It is used alongside a planned quit attempt, behavioural support, and practical changes to smoking routines. The aim is to reduce withdrawal symptoms while weakening the reward associated with smoking.
Smoking cessation medicines can be useful when cravings, irritability, poor concentration, or repeated relapse make quitting difficult. The World Health Organization recommends combining pharmacological treatment with behavioural support because the two approaches address different parts of nicotine dependence [1].
A quit date is commonly agreed before treatment starts. Some treatment plans begin varenicline before that date, allowing the medicine to build its effect while the person prepares to stop smoking.
The tablets contain no nicotine. This distinguishes varenicline from nicotine replacement therapy, which supplies controlled amounts of nicotine through products such as patches, gum, lozenges, or sprays. Champix works through receptor activity rather than nicotine replacement.
Varenicline tartrate is the salt form used to provide varenicline in Champix tablets. The medicine does not deliver nicotine, so it does not maintain nicotine exposure in the same way as nicotine replacement therapy.
The product presentation contains 1 mg film-coated tablets.
Varenicline attaches to alpha-4 beta-2 nicotinic acetylcholine receptors, the same receptor family activated by nicotine. It acts as a partial agonist, producing enough receptor stimulation to reduce withdrawal while blocking much of nicotine’s stronger rewarding effect.
This creates two practical effects:
The receptor effect is gradual rather than immediate. Clinical evidence reviewed by the European Medicines Agency supports varenicline as a pharmacological option for smoking cessation [2].
Champix is taken orally as film-coated tablets. The amount per intake is set individually for each person rather than being one fixed number for every patient. The treatment plan normally uses gradual dose adjustment at the beginning, followed by the prescribed maintenance dose.
A prescriber may use a lower starting amount during titration, with the schedule selected according to tolerability, kidney function, and the intended quit date.
A typical clinical plan follows this pattern:
Do not create your own titration schedule by cutting tablets or changing the number of tablets. Varenicline dosing requires individual assessment, especially in people with reduced kidney function.
Take each dose with a full glass of water. Taking Champix after food can reduce nausea for some people. Swallow the tablet whole unless a prescriber has given a specific alternative instruction.
If a dose is missed, take it when remembered unless the next dose is due soon. Do not take two doses together to compensate. A double dose can increase nausea, dizziness, vomiting, or other adverse effects.
Different stop-smoking treatments act through different pathways. Choice depends on nicotine dependence, previous treatment response, kidney function, mental health history, pregnancy status, and personal preference.
| Treatment approach | Main pharmacological action | Practical distinction |
|---|---|---|
| Champix, varenicline | Partial agonist at alpha-4 beta-2 nicotinic receptors | Reduces cravings and weakens nicotine reward without supplying nicotine |
| Nicotine replacement therapy | Supplies controlled nicotine | Can be adjusted through patches, gum, lozenges, sprays, or other forms |
| Bupropion | Acts on noradrenaline and dopamine pathways | Does not contain nicotine but has specific seizure and interaction restrictions |
Varenicline may suit someone who wants a non-nicotine treatment that directly targets the brain’s nicotine reward pathway. Nicotine replacement therapy can be useful when flexible control of withdrawal is preferred, especially with a long-acting patch combined with a short-acting product for breakthrough cravings.
Bupropion is pharmacologically different from both approaches. It is unsuitable for people with certain seizure risks and requires careful review of other medicines. The choice is clinical, not a matter of selecting the strongest tablet.
The best option also depends on adherence. A theoretically suitable treatment has limited value if nausea, complex dosing, or sleep disturbance makes regular use difficult.
Several avoidable errors can reduce the chance of a successful quit attempt:
The tablet should be swallowed whole. Crushing or chewing can alter how the dose is released and may worsen local irritation or unpleasant taste.
A lapse does not have to become a relapse. Record what triggered it, remove the remaining cigarettes, and return to the agreed cessation plan. Persistent smoking during treatment should be discussed with the prescribing clinician because it may signal that additional behavioural support is needed.
Varenicline is eliminated largely through the kidneys. Kidney function therefore matters more than liver function when determining exposure. A clinician may adjust the dose when renal clearance is reduced.
Champix has relatively few direct metabolic interactions because it is not extensively processed by liver enzyme systems. Nicotine replacement, alcohol, sedatives, antidepressants, antipsychotics, and medicines affected by smoking cessation still deserve specific review.
Do not combine Champix with another stop-smoking medicine without an agreed plan. Combining treatments can increase nausea, dizziness, sleep problems, or other adverse effects.
Champix may not be right for you if you have had an allergic reaction to it, have serious kidney problems, are pregnant or breastfeeding, or are under 18. Tell your prescriber if you have a history of depression, bipolar disorder, psychosis, severe anxiety, seizures, or suicidal behaviour. You should also discuss all medicines and any plan to use nicotine replacement, alcohol, sedatives, or other stop-smoking products before starting treatment.
Nausea is the most frequently reported adverse effect associated with varenicline. Headache, insomnia, abnormal dreams, dizziness, constipation, dry mouth, and indigestion can also occur. The FDA prescribing information describes these reactions and provides the main safety framework for varenicline treatment [3].
Common effects may be managed in practical ways:
Vivid or unusual dreams can be memorable and unsettling. They do not automatically mean that treatment must stop, but severe sleep disruption deserves prompt review. Sleep disturbance can also result from nicotine withdrawal, caffeine changes, or anxiety about quitting, so the timing and severity of symptoms matter.
Mood changes require attention. Agitation, depressed mood, unusual aggression, suicidal thoughts, or behaviour that feels out of character require urgent medical assessment. The MHRA has highlighted the need to monitor neuropsychiatric symptoms in people receiving varenicline, especially when there is a history of depression or other mental health conditions.
Some people find that cravings fall without major problems. Others stop treatment because nausea or dreams are too disruptive. Individual tolerability determines whether the benefit is worth continuing, and dose adjustment may be needed.
Seek urgent medical help for facial or throat swelling, breathing difficulty, widespread blistering rash, collapse, severe confusion, or thoughts of self-harm.
One practical detail is easy to miss: stopping smoking can alter the effects of medicines affected by tobacco smoke, even when Champix itself has limited drug interactions. The prescriber may need to review medicines such as clozapine, olanzapine, theophylline, or warfarin after smoking stops.
In clinical practice, prescribers usually focus on three questions: whether the person is ready to set a quit date, whether varenicline is medically suitable, and whether the patient can follow the titration plan.
The treatment works best when the person treats cravings as temporary symptoms rather than instructions to smoke. A craving often rises, peaks, and fades within a short period, even when it feels urgent. Removing cigarettes, lighters, and ashtrays before the quit date also reduces automatic smoking.
Doctors pay close attention to mood and sleep. A new mental health symptom should not be dismissed as ordinary withdrawal, especially if it is severe, persistent, or accompanied by self-harm thoughts.
The National Institute for Health and Care Excellence supports structured tobacco-dependence treatment that combines behavioural help with pharmacological options where appropriate [4]. Varenicline is one part of that plan, not a replacement for preparation and follow-through.
A prescriber may also ask about previous attempts with nicotine replacement or bupropion. Earlier treatment failure does not prove that varenicline will fail, because its receptor mechanism differs.
Nausea is a well-recognised adverse effect of varenicline and is listed in regulatory safety information from the FDA and EMA. Taking Champix after food with water can reduce the problem for some people, although it may not remove it completely. Persistent vomiting, inability to keep fluids down, or severe abdominal symptoms require prompt medical assessment. The 2026 clinical approach remains to balance symptom severity against the benefit of continuing treatment.
Champix film-coated tablets should be swallowed whole with water rather than split, crushed, or chewed. The film coating and tablet design are intended for oral administration as supplied. The EMA product information describes whole-tablet administration and dose adjustment through prescribed strengths or schedules, not home alteration of the tablet. This advice remains relevant in 2026 because changing the tablet can produce an unpleasant taste and make dosing less predictable.
Combining varenicline with nicotine replacement can increase adverse effects such as nausea, headache, dizziness, and indigestion, so the combination should be planned by a prescriber. The MHRA advises attention to tolerability and individual risk when smoking-cessation medicines are used. Supplements are not automatically interaction-free, especially products containing stimulants, sedatives, or multiple herbal ingredients. Provide a complete list of medicines and supplements before the treatment plan is finalised.
Take the missed dose when remembered unless the next scheduled dose is close. Do not take two doses together, because doubling may worsen nausea, dizziness, vomiting, or sleep disturbance. The NHS approach to missed medicines supports returning to the normal schedule rather than compensating with an extra dose. If missed doses occur repeatedly, a pharmacist or prescriber can help adapt the routine.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
Sunderland, used the prescribed dose during a planned treatment course. He reported that cravings became less intrusive after the first week and cigarettes stopped feeling rewarding. Nausea was noticeable when he took a dose before breakfast, but it eased after switching to food.
Sunderland During a planned treatment course 27 Oct 2026York, used the prescribed dose during treatment and stopped smoking, but found the dreams unusually vivid for several nights. She felt the cravings were more manageable than during earlier unaided attempts, although poor sleep made the first fortnight tiring.
York During treatment 30 Sept 2026Newcastle upon Tyne, used the prescribed dose during the planned treatment course with support from his general practice. He still smoked occasionally during the first part of the plan and became frustrated by the slow progress. His breathing improved after he eventually stopped, but constipation and dry mouth made the treatment less comfortable than expected.
Newcastle upon Tyne During the planned treatment course 4 Oct 2026
